[{"id":"243bbd2b-9fa8-4a47-8997-af40c6654b26","acronym":"SEL-TH-1601","url":"https://clinicaltrials.gov/study/NCT03095248","created_at":"2021-01-18T15:15:00.040Z","updated_at":"2025-02-25T14:57:54.989Z","phase":"Phase 2","brief_title":"Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors","source_id_and_acronym":"NCT03095248 - SEL-TH-1601","lead_sponsor":"Children's Hospital Medical Center, Cincinnati","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 05/21/2024","primary_completion_date":" 05/21/2024","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2024-10-04"},{"id":"80d81649-784d-4aaa-986f-3c25d334fd80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665206","created_at":"2023-08-24T11:08:27.232Z","updated_at":"2024-07-02T16:35:04.273Z","phase":"Phase 1/2","brief_title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations","source_id_and_acronym":"NCT04665206","lead_sponsor":"Vivace Therapeutics, Inc","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VT3989"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 06/02/2027","study_completion_date":" 06/02/2027","last_update_posted":"2024-05-13"},{"id":"f0d76f28-ae07-45db-b977-f3917bda1843","acronym":"EAY131-U","url":"https://clinicaltrials.gov/study/NCT04439331","created_at":"2023-08-24T11:08:26.432Z","updated_at":"2024-07-02T16:35:04.943Z","phase":"Phase 2","brief_title":"Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)","source_id_and_acronym":"NCT04439331 - EAY131-U","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-08"},{"id":"e4bb6ebb-d0a1-45a9-8623-25eb132314cd","acronym":"POPLAR-NF2","url":"https://clinicaltrials.gov/study/NCT05130866","created_at":"2023-08-24T11:08:27.986Z","updated_at":"2024-07-02T16:35:16.781Z","phase":"Phase 2/3","brief_title":"Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas","source_id_and_acronym":"NCT05130866 - POPLAR-NF2","lead_sponsor":"Recursion Pharmaceuticals Inc.","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-2282"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-03-01"},{"id":"095b86fa-4f3e-4ef0-b5ca-58c5116b56f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05521048","created_at":"2022-08-30T20:55:54.949Z","updated_at":"2024-07-02T16:35:32.651Z","phase":"Phase 1/2","brief_title":"Doxycycline in Cutaneous Schwannoma (NF2)","source_id_and_acronym":"NCT05521048","lead_sponsor":"Massachusetts Eye and Ear Infirmary","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 09/19/2022","start_date":" 09/19/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-19"},{"id":"05930b4c-873d-4e4a-9994-ebc8a0165de0","acronym":"NF110","url":"https://clinicaltrials.gov/study/NCT04283669","created_at":"2021-01-18T20:47:46.146Z","updated_at":"2024-07-02T16:35:37.504Z","phase":"Phase 2","brief_title":"Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas","source_id_and_acronym":"NCT04283669 - NF110","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 02/18/2020","start_date":" 02/18/2020","primary_txt":" Primary completion: 08/18/2025","primary_completion_date":" 08/18/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-11"},{"id":"7b27da0a-d639-42fd-a136-368d479a1f3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02831257","created_at":"2021-01-18T13:53:02.982Z","updated_at":"2025-02-25T15:07:09.140Z","phase":"Phase 2","brief_title":"AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas","source_id_and_acronym":"NCT02831257","lead_sponsor":"Massachusetts General Hospital","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vistusertib (AZD2014)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 08/31/2016","start_date":" 08/31/2016","primary_txt":" Primary completion: 05/31/2019","primary_completion_date":" 05/31/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2022-06-13"},{"id":"088b091f-0df4-4cf7-9c2b-0f890fcab1ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT01207687","created_at":"2021-01-18T04:50:27.780Z","updated_at":"2024-07-02T16:37:07.472Z","phase":"Phase 2","brief_title":"Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)","source_id_and_acronym":"NCT01207687","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2018-08-27"}]